Ana M Rodríguez-Piñeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana M Rodríguez-Piñeiro has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
M. Páez de la Cadena
Departamento de Bioquímica, Genética e Inmunología, Universidad de Vigo, Vigo, Spain
2 shared publicationsS. Blanco-Prieto
Departamento de Bioquímica, Genética e Inmunología, Universidad de Vigo, Vigo, Spain
2 shared publicationsA. García-Lorenzo
Departamento de Bioquímica, Genética e Inmunología, Universidad de Vigo, Vigo, Spain
1 shared publication- David Martínez-Ares
Complejo Hospitalario Universitario de Vigo. Servicio de Digestivo. Calle Pizarro 22. 36204 Vigo, Spain
1 shared publication F. J. Rodríguez-Berrocal
Departamento de Bioquímica, Genética e Inmunología, Universidad de Vigo, Vigo, Spain
1 shared publicationF.J. Rodríguez-Berrocal
Departamento de Bioquímica, Genética e Inmunología, Facultad de Biología, Universidad de Vigo, Campus Universitario, 36310 Vigo, Spain
1 shared publication
Latest Publications
- 31 January 2012
- Published by Taylor & Francis in Cancer Investigation
- Vol. 30 (1) , 72-78
Secreted Clusterin in Colon Tumor Cell Models and Its Potentialas Diagnostic Marker for Colorectal Cancer
We studied the specific changes of the secreted protein clusterin and its cytoplasmic precursor regarding colorectal tumorigenesis, using in vitro differentiation of Caco-2 cells. In tumor-like stage, we observed an overexpression of both precursor and secreted clusterin, corroborated in the cell line SW-480. Noticeably, SW-620 cells (from a tumoral node, thus with metastatic capacity) did not show overexpression of either precursor or secreted clusterin, suggesting a downregulation related to local metastasis. We further investigated clusterin in serum, finding a significant increase in colorectal cancer patients, with 81% sensitivity, 79% specificity, and an area under the ROC curve of 0.85.
- 31 January 2012
- Published by Taylor & Francis in Cancer Investigation
- Vol. 30 (1) , 72-78
Secreted Clusterin in Colon Tumor Cell Models and Its Potentialas Diagnostic Marker for Colorectal Cancer
We studied the specific changes of the secreted protein clusterin and its cytoplasmic precursor regarding colorectal tumorigenesis, using in vitro differentiation of Caco-2 cells. In tumor-like stage, we observed an overexpression of both precursor and secreted clusterin, corroborated in the cell line SW-480. Noticeably, SW-620 cells (from a tumoral node, thus with metastatic capacity) did not show overexpression of either precursor or secreted clusterin, suggesting a downregulation related to local metastasis. We further investigated clusterin in serum, finding a significant increase in colorectal cancer patients, with 81% sensitivity, 79% specificity, and an area under the ROC curve of 0.85.
- Open Access
- 28 June 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 333
Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas
Background: Serum CD26 (sCD26) levels were previously found diminished in colorectal cancer (CRC) patients compared to healthy donors, suggesting its potential utility for early diagnosis. Therefore we aimed to estimate the utility of the sCD26 as a biomarker for CRC and advanced adenomas in a high-risk group of patients. The relationship of this molecule with polyp characteristics was also addressed. Methods: sCD26 levels were measured by ELISA in 299 symptomatic and asymptomatic patients who had undergone a colonoscopy. Patients were diagnosed as having no colorectal pathology, non-inflammatory or inflammatory bowel disease, polyps (hyperplastic, non-advanced and advanced adenomas) or CRC. Results: At a 460 ng/mL cut-off, the sCD26 has a sensitivity and specificity of 81.8% (95% CI, 64.5-93.0%) and 72.3% (95% CI, 65.0-77.2%) for CRC regarding no or benign colorectal pathology. Clinicopathological analysis of polyps showed a relationship between the sCD26 and the grade of dysplasia and the presence of advanced adenomas. Hence, a 58.0% (95% CI, 46.5-68.9%) sensitivity detecting CRC and advanced adenomas was obtained, with a specificity of 75.5% (95% CI, 68.5-81.0%). Conclusions: Our preliminary results show that measurement of the sCD26 is a non-invasive and reasonably sensitive assay, which could be combined with others such as the faecal occult blood test for the early diagnosis and screening of CRC and advanced adenomas. Additional comparative studies in average-risk populations are necessary.
- 28 June 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 333
Open AccessSerum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas
Background: Serum CD26 (sCD26) levels were previously found diminished in colorectal cancer (CRC) patients compared to healthy donors, suggesting its potential utility for early diagnosis. Therefore we aimed to estimate the utility of the sCD26 as a biomarker for CRC and advanced adenomas in a high-risk group of patients. The relationship of this molecule with polyp characteristics was also addressed. Methods: sCD26 levels were measured by ELISA in 299 symptomatic and asymptomatic patients who had undergone a colonoscopy. Patients were diagnosed as having no colorectal pathology, non-inflammatory or inflammatory bowel disease, polyps (hyperplastic, non-advanced and advanced adenomas) or CRC. Results: At a 460 ng/mL cut-off, the sCD26 has a sensitivity and specificity of 81.8% (95% CI, 64.5-93.0%) and 72.3% (95% CI, 65.0-77.2%) for CRC regarding no or benign colorectal pathology. Clinicopathological analysis of polyps showed a relationship between the sCD26 and the grade of dysplasia and the presence of advanced adenomas. Hence, a 58.0% (95% CI, 46.5-68.9%) sensitivity detecting CRC and advanced adenomas was obtained, with a specificity of 75.5% (95% CI, 68.5-81.0%). Conclusions: Our preliminary results show that measurement of the sCD26 is a non-invasive and reasonably sensitive assay, which could be combined with others such as the faecal occult blood test for the early diagnosis and screening of CRC and advanced adenomas. Additional comparative studies in average-risk populations are necessary.
- 1 June 2010
- Published by Elsevier in Journal of Proteomics
- Vol. 73 (8) , 1511-1522
On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion
- 1 June 2010
- Published by Elsevier in Journal of Proteomics
- Vol. 73 (8) , 1511-1522
On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion